Literature DB >> 27764083

Status of New Vaccine Introduction - Worldwide, September 2016.

Anagha Loharikar, Laure Dumolard, Susan Chu, Terri Hyde, Tracey Goodman, Carsten Mantel.   

Abstract

Since the global Expanded Program on Immunization (EPI) was launched in 1974, vaccination against six diseases (tuberculosis, polio, diphtheria, tetanus, pertussis, and measles) has prevented millions of deaths and disabilities (1). Significant advances have been made in the development and introduction of vaccines, and licensed vaccines are now available to prevent 25 diseases (2,3). Historically, new vaccines only became available in low-income and middle-income countries decades after being introduced in high-income countries. However, with the support of global partners, including the World Health Organization (WHO) and the United Nations Children's Fund, which assist with vaccine prequalification and procurement, as well as Gavi, the Vaccine Alliance (Gavi) (4), which provides funding and shapes vaccine markets through forecasting and assurances of demand in low-income countries in exchange for lower vaccine prices, vaccines are now introduced more rapidly. Based on data compiled in the WHO Immunization Vaccines and Biologicals Database* (5), this report describes the current status of introduction of Haemophilus influenzae type b (Hib), hepatitis B, pneumococcal conjugate, rotavirus, human papillomavirus, and rubella vaccines, and the second dose of measles vaccine. As of September 2016, a total of 191 (99%) of 194 WHO member countries had introduced Hib vaccine, 190 (98%) had introduced hepatitis B vaccine, 132 (68%) had introduced pneumococcal conjugate vaccine (PCV), and 86 (44%) had introduced rotavirus vaccine into infant vaccination schedules. Human papillomavirus vaccine (HPV) had been introduced in 67 (35%) countries, primarily targeted for routine use in adolescent girls. A second dose of measles-containing vaccine (MCV2) had been introduced in 161 (83%) countries, and rubella vaccine had been introduced in 149 (77%). These efforts support the commitment outlined in the Global Vaccine Action Plan (GVAP), 2011-2020 (2), endorsed by the World Health Assembly in 2012, to extend the full benefits of immunization to all persons.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27764083     DOI: 10.15585/mmwr.mm6541a3

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  15 in total

1.  Geospatial Planning and the Resulting Economic Impact of Human Papillomavirus Vaccine Introduction in Mozambique.

Authors:  Leila A Haidari; Shawn T Brown; Dagna Constenla; Eli Zenkov; Marie Ferguson; Gatien de Broucker; Sachiko Ozawa; Samantha Clark; Allison Portnoy; Bruce Y Lee
Journal:  Sex Transm Dis       Date:  2017-04       Impact factor: 2.830

2.  Global Rotavirus and Pneumococcal Conjugate Vaccine Introductions and the Association With Country Disease Surveillance, 2006-2018.

Authors:  Megan E Peck; Lee M Hampton; Sebastian Antoni; Ike Ogbuanu; Fatima Serhan; Tomoka Nakamura; Jenny A Walldorf; Adam L Cohen
Journal:  J Infect Dis       Date:  2021-09-01       Impact factor: 7.759

Review 3.  Rotavirus Vaccines: Effectiveness, Safety, and Future Directions.

Authors:  Eleanor Burnett; Umesh Parashar; Jacqueline Tate
Journal:  Paediatr Drugs       Date:  2018-06       Impact factor: 3.022

4.  School-based delivery of routinely recommended vaccines and opportunities to check vaccination status at school, a global summary, 2008-2017.

Authors:  Leora R Feldstein; Garrett Fox; Abigail Shefer; Laura M Conklin; Kirsten Ward
Journal:  Vaccine       Date:  2019-11-01       Impact factor: 3.641

5.  Hospitalisation for lower respiratory tract infection in children in the province of Quebec, Canada, before and during the pneumococcal conjugate vaccine era.

Authors:  G Anderson; G Deceuninck; Z Zhou; F D Boucher; Y Bonnier Viger; R Gilca; P De Wals
Journal:  Epidemiol Infect       Date:  2017-08-14       Impact factor: 4.434

6.  Rapid replacement by non-vaccine pneumococcal serotypes may mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial ecology.

Authors:  Brenda Kwambana-Adams; Blake Hanson; Archibald Worwui; Schadrac Agbla; Ebenezer Foster-Nyarko; Fatima Ceesay; Chinelo Ebruke; Uzochukwu Egere; Yanjiao Zhou; Maze Ndukum; Erica Sodergren; Michael Barer; Richard Adegbola; George Weinstock; Martin Antonio
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

Review 7.  Streptococcus pneumoniae Otitis Media Pathogenesis and How It Informs Our Understanding of Vaccine Strategies.

Authors:  Caroline Bergenfelz; Anders P Hakansson
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-05-20

8.  Rubella virus infection and associated factors among pregnant women attending the antenatal care clinics of public hospitals in Hawassa City, Southern Ethiopia: a cross-sectional study.

Authors:  Biniam Tamirat; Siraj Hussen; Techalew Shimelis
Journal:  BMJ Open       Date:  2017-10-05       Impact factor: 2.692

9.  Identification of vaccine-derived rotavirus strains in children with acute gastroenteritis in Japan, 2012-2015.

Authors:  Mei Kaneko; Sayaka Takanashi; Aksara Thongprachum; Nozomu Hanaoka; Tsuguto Fujimoto; Koo Nagasawa; Hirokazu Kimura; Shoko Okitsu; Masashi Mizuguchi; Hiroshi Ushijima
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

10.  Strengthening Care Delivery in Primary Care Facilities: Perspectives of Facility Managers on the Immunization Program in Kenya.

Authors:  Rose N Chesoli; Roseanne C Schuster; Stephen Okelo; Moshood O Omotayo
Journal:  Int J Health Policy Manag       Date:  2018-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.